Bajaj Healthcare Ltd. on Friday said it has successfully completed the U.S. health regulator's pre-approval inspection of its active pharmaceutical ingredients facility located at Vadodara in Gujarat.
The U.S. Food and Drug Administration had conducted a pre-approval inspection of the facility from Nov. 14, 2022, to Nov. 17, 2022, Bajaj Healthcare said in a regulatory filing.
The pre-approval inspection has completed successfully with zero Form 483 observations of the manufacturing facility, said the company, which is a manufacturer of APIs, intermediates and formulations. Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator observes any conditions that may constitute violations of the Food Drug and Cosmetic Act and related Acts.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-08-27/50wxe5pb/GV5y8MwW4AAgisw.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Heavy Rains In Gujarat Claim Seven Lives, Over 6,000 Evacuated
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-08-26/z83swf4m/Assortment_colorful_pills_arranged_for_photograph___Source_freepik_.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
USFDA Issues Recalls: Aurobindo Pharma, Glenmark Pharma, And FDC Comply
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-08-23/4xg8byhq/Greenply_company website.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Greenply Eyes 7% Furniture Hardware Market Share With Upcoming Vadodara Unit
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-07/b5a9af3c-4932-4784-93b2-b2efc8454ee8/Glenmark Pharmaceuticals website.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Glenmark's Anti-Seizure Drug Approved By USFDA
![timelogo](/images/amp-time.png)